A new scoping review examines the impact of respiratory bacteria on the severity of respiratory syncytial virus (RSV) ...

A nationwide surge in flu, COVID-19, RSV and norovirus infections is fueling concerns of a possible virus "quademic." Or is it just winter? The three respiratory viruses plus norovirus ...

Meanwhile, RSV remains a major cause of infant morbidity ... The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

The study, published Jan. 20 in The Lancet Infectious Diseases, found the vaccine to be 78% effective against RSV infection, 79% effective against emergency department and urgent care visits and 80% ...

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children under two years old, resulting in significant morbidity and a heavy economic burden on healthcare ...

The U.S. is seeing a "quad-demic" as cases of COVID-19, flu, RSV and norovirus spread at the same time. Experts said this is what you need to know. The so-called "quad-demic" includes flu ...

Concerns about GBS arose during the review of safety data from clinical ... of lower respiratory tract disease (LRTD) associated with RSV in adults aged 60 years or more, and has since been ...

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...